Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy
Donglu Wu, Ye Qiu, Yunshuang Jiao, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 62

Showing 1-25 of 62 citing articles:

Pathological implication of protein post-translational modifications in cancer
Sheng Pan, Ru Chen
Molecular Aspects of Medicine (2022) Vol. 86, pp. 101097-101097
Open Access | Times Cited: 129
The role of altered protein acetylation in neurodegenerative disease
Fariha Kabir, Rachel A.K. Atkinson, Anthony L. Cook, et al.
Frontiers in Aging Neuroscience (2023) Vol. 14
Open Access | Times Cited: 37
Multiple therapeutic approaches of glioblastoma multiforme: From terminal to therapy
Smita Kumari, Rohan Gupta, Rashmi K. Ambasta, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 4, pp. 188913-188913
Closed Access | Times Cited: 24
Dysregulation of different modes of programmed cell death by epigenetic modifications and their role in cancer
Roxana Damiescu, Thomas Efferth, Mona Dawood
Cancer Letters (2024) Vol. 584, pp. 216623-216623
Open Access | Times Cited: 11
A systematic review of epigenetic interplay in kidney diseases: Crosstalk between long noncoding RNAs and methylation, acetylation of chromatin and histone
Ruizhi Tan, Jian Jia, Tong Li, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 176, pp. 116922-116922
Open Access | Times Cited: 9
Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy
Chong Feng, Lening Zhang, Xin Chang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 19
BRD4: New hope in the battle against glioblastoma
Weichen Duan, Miao Yu, Jiajia Chen
Pharmacological Research (2023) Vol. 191, pp. 106767-106767
Open Access | Times Cited: 18
The pharmacoepigenetic paradigm in cancer treatment
Belén Ocaña-Paredes, Sebastián Rivera-Orellana, David Ramírez, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 7
Bromodomain-Containing Protein 9 Regulates Signaling Pathways and Reprograms the Epigenome in Immortalized Human Uterine Fibroid Cells
Qiwei Yang, Somayeh Vafaei, Ali Falahati, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 905-905
Open Access | Times Cited: 6
Role of Epigenetics for the Efficacy of Cisplatin
Tatjana Lumpp, Sandra Stößer, Franziska Fischer, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1130-1130
Open Access | Times Cited: 6
Emerging role of PD-L1 modification in cancer immunotherapy.
Xiaoli Hu, Zixia Lin, Zhiwei Wang, et al.
American Journal of Cancer Research (2021) Vol. 11, Iss. 8, pp. 3832-3840
Closed Access | Times Cited: 33
Epigenetic modulations in cancer: predictive biomarkers and potential targets for overcoming the resistance to topoisomerase I inhibitors
Moustafa M. Madkour, Wafaa S. Ramadan, Ekram Saleh, et al.
Annals of Medicine (2023) Vol. 55, Iss. 1
Open Access | Times Cited: 14
Alzheimer’s Disease-Related Epigenetic Changes: Novel Therapeutic Targets
Alireza Paniri, Mohammad Mahdi Hosseini, Haleh Akhavan‐Niaki
Molecular Neurobiology (2023) Vol. 61, Iss. 3, pp. 1282-1317
Closed Access | Times Cited: 13
Current trends in clinical trials and the development of small molecule epigenetic inhibitors as cancer therapeutics
Nazanin Zohourian, James A. L. Brown
Epigenomics (2024) Vol. 16, Iss. 9, pp. 671-680
Closed Access | Times Cited: 5
Histone Acetylation and Modifiers in Renal Fibrosis
Fengchen Shen, Shougang Zhuang
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 20
The MOZ-BRPF1 acetyltransferase complex in epigenetic crosstalk linked to gene regulation, development, and human diseases
Tiina Viita, Jacques Côté
Frontiers in Cell and Developmental Biology (2023) Vol. 10
Open Access | Times Cited: 12
Implication of protein post translational modifications in gastric cancer
Houji Song, Mingze Zhang, Chengwang Guo, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 13
Open Access
Histone acetylation modulators in breast cancer
Xueying Yuan, Jeffrey M. Rosen
Breast Cancer Research (2025) Vol. 27, Iss. 1
Open Access
N-1,2,3-Triazole–isatin derivatives: anti-proliferation effects and target identification in solid tumour cell lines
Natalia Busto, Joana Leitão-Castro, Alfonso T. García‐Sosa, et al.
RSC Medicinal Chemistry (2022) Vol. 13, Iss. 8, pp. 970-977
Open Access | Times Cited: 17
The NF-κB Pharmacopeia: Novel Strategies to Subdue an Intractable Target
Daniela Verzella, Jessica Cornice, Paola Arboretto, et al.
Biomedicines (2022) Vol. 10, Iss. 9, pp. 2233-2233
Open Access | Times Cited: 17
Neuropeptides in Cancer: Friend and Foe?
Yue Wu, Adrian Berisha, Jeremy C. Borniger
Advanced Biology (2022) Vol. 6, Iss. 9
Closed Access | Times Cited: 16
Restoration of WT1/miR-769-5p axis by HDAC1 inhibition promotes MMT reversal in mesenchymal-like mesothelial cells
Giulio Bontempi, Michela Terri, Sabrina Garbo, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 11
Open Access | Times Cited: 16
Focused Libraries for Epigenetic Drug Discovery: The Importance of Isosteres
Adam I. Green, George M. Burslem
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 11, pp. 7231-7240
Closed Access | Times Cited: 17
CBX4-dependent regulation of HDAC3 nuclear translocation reduces Bmp2-induced osteoblastic differentiation and calcification in adamantinomatous craniopharyngioma
Xiaorong Yan, De-Zhi Kang, Yuanxiang Lin, et al.
Cell Communication and Signaling (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 12
Benzimidazole‐Containing Compounds as Anticancer Agents
Ulviye Acar Çevik, Ayşen Işık, Betül Kaya, et al.
ChemistrySelect (2024) Vol. 9, Iss. 32
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top